Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Precigen, Inc.
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
The new collaboration announced 17 August is worth up to $475m in near-term upfront payments plus undisclosed milestone fees and royalties up to 24%.
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.
Five-year collaboration will analyze data from thousands of cancer patients to optimize immunotherapy treatment and develop PET imaging tracers to stratify clinical trial participants. Also, MD Anderson starts 2019 with three new agreements.
- Research, Analytical Equipment & Supplies
- Gene Therapy, Cell Therapy
- Large Molecule
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Molecular Diversity
- Other Names / Subsidiaries
- ActoBio Therapeutics, Inc.
- ActoGeniX N.V.
- Exemplar Genetics
- GenVec, Inc.
- Immunologix, Inc.
- Intrexon ActoBiotics Division
- Intrexon Corporation (XON)
- Intrexon Health
- Intrexon T1D Partners, LLC (Joint Venture)
- MediStem Inc.
- MBP Titan LLC
- Trans Ova Genetics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.